EA202091732A1 - Конструкты нуклеиновых кислот и вакцины из больших и малых т-антигенов полиомавируса клеток меркеля и способы их применения - Google Patents

Конструкты нуклеиновых кислот и вакцины из больших и малых т-антигенов полиомавируса клеток меркеля и способы их применения

Info

Publication number
EA202091732A1
EA202091732A1 EA202091732A EA202091732A EA202091732A1 EA 202091732 A1 EA202091732 A1 EA 202091732A1 EA 202091732 A EA202091732 A EA 202091732A EA 202091732 A EA202091732 A EA 202091732A EA 202091732 A1 EA202091732 A1 EA 202091732A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
mcv
antigens
nucleic acid
poliomavirus
Prior art date
Application number
EA202091732A
Other languages
English (en)
Inventor
Дэвид Б. Уэйнер
Элизабет Дюперре
Original Assignee
Дзе Уистар Инститьют Оф Энэтоми Энд Байолоджи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Уистар Инститьют Оф Энэтоми Энд Байолоджи filed Critical Дзе Уистар Инститьют Оф Энэтоми Энд Байолоджи
Publication of EA202091732A1 publication Critical patent/EA202091732A1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/58Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/22011Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Молекулы и композиции нуклеиновых кислот, содержащие одну или более нуклеотидных последовательностей, кодирующих консенсусный T-антиген полиомавируса клеток Меркеля (MCV). Раскрыты иммуномодулирующие способы и способы индукции иммунного ответа против MCV. Раскрыт способ лечения инфекции MCV и способы лечения или профилактики карциномы клеток Меркеля, связанной с MCV. Раскрыты модифицированные консенсусные T-антигены MCV.
EA202091732A 2018-01-19 2019-01-18 Конструкты нуклеиновых кислот и вакцины из больших и малых т-антигенов полиомавируса клеток меркеля и способы их применения EA202091732A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862619161P 2018-01-19 2018-01-19
PCT/US2019/014171 WO2019143921A2 (en) 2018-01-19 2019-01-18 Large and small t antigens of merkel cell polyomavirus, nucleic acid constructs and vaccines made therefrom, and methods of using same

Publications (1)

Publication Number Publication Date
EA202091732A1 true EA202091732A1 (ru) 2020-09-10

Family

ID=67302504

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202091732A EA202091732A1 (ru) 2018-01-19 2019-01-18 Конструкты нуклеиновых кислот и вакцины из больших и малых т-антигенов полиомавируса клеток меркеля и способы их применения

Country Status (11)

Country Link
US (2) US11524065B2 (ru)
EP (1) EP3740226A4 (ru)
JP (1) JP7485604B2 (ru)
KR (1) KR20200110678A (ru)
CN (1) CN111801111A (ru)
AU (1) AU2019210063A1 (ru)
BR (1) BR112020014632A2 (ru)
CA (1) CA3088374A1 (ru)
EA (1) EA202091732A1 (ru)
MX (1) MX2020007676A (ru)
WO (1) WO2019143921A2 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111801111A (zh) * 2018-01-19 2020-10-20 威斯塔解剖学和生物学研究所 梅克尔多元癌细胞病毒的大和小t抗原、核酸构建体和由此制造的疫苗及其使用方法
WO2021247534A2 (en) * 2020-06-01 2021-12-09 The Broad Institute, Inc. Compositions and methods for treating merkel cell carcinoma (mcc) using hla class i specific epitopes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004510714A (ja) * 2000-10-04 2004-04-08 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア フラビウイルス及びペスチウイルス由来のキャプシド蛋白質を使用する組成物及び方法
WO2016073595A1 (en) * 2014-11-05 2016-05-12 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services T cells and dendritic cells for polyomavirus therapy
EP3101134A1 (en) * 2015-06-05 2016-12-07 Apcure SAS Therapeutic vaccine for treating or preventing merkel cell polyoma virus-associated tumors
WO2017060283A1 (en) * 2015-10-06 2017-04-13 Universität Basel Specific immunodominant peptide epitopes for polyomavirus vaccine
CN111801111A (zh) * 2018-01-19 2020-10-20 威斯塔解剖学和生物学研究所 梅克尔多元癌细胞病毒的大和小t抗原、核酸构建体和由此制造的疫苗及其使用方法

Also Published As

Publication number Publication date
CA3088374A1 (en) 2019-07-25
EP3740226A2 (en) 2020-11-25
BR112020014632A2 (pt) 2021-01-05
JP7485604B2 (ja) 2024-05-16
US20230201328A1 (en) 2023-06-29
CN111801111A (zh) 2020-10-20
MX2020007676A (es) 2020-11-12
AU2019210063A1 (en) 2020-08-20
KR20200110678A (ko) 2020-09-24
EP3740226A4 (en) 2021-10-13
WO2019143921A3 (en) 2020-04-09
JP2021511320A (ja) 2021-05-06
US11524065B2 (en) 2022-12-13
WO2019143921A2 (en) 2019-07-25
US20200345830A1 (en) 2020-11-05

Similar Documents

Publication Publication Date Title
CY1121215T1 (el) Αντιικα εμβολια με βελτιωμενη κυτταρικη ανοσογονικοτητα
MX2020004578A (es) Composiciones de casz y metodos de uso.
EA201992001A1 (ru) Композиции и способы повышения экспрессии генов
EA202092808A1 (ru) Вакцины на основе наночастиц с новыми структурными компонентами
EA201990861A1 (ru) Рнк-направляемые модифицирующие нуклеиновые кислоты ферменты и способы их применения
EA201890355A1 (ru) Новые способы индукции иммунного ответа
EA201990937A1 (ru) Цитомегаловирусные векторы, выбирающие t-клетки, ограниченные по молекулам главного комплекса гистосовместимости e
BR112016027897A2 (pt) polipeptídio multimérico, ácido nucleico, vetor de expressão recombinante, célula hospedeira geneticamente modificada, composição, método, e, método de tratamento de uma infecção num indivíduo
SG10201901053TA (en) Novel tilapia virus and uses thereof
EA201690529A1 (ru) Способы модификации клетки-хозяина
BR112018073238A2 (pt) vírus oncolíticos compreendendo esrage e métodos de tratamento de câncer
ZA202206809B (en) Hiv vaccines comprising one or more population episensus antigens
WO2019226939A8 (en) Immune checkpoint inhibitor co-expression vectors
EA202091732A1 (ru) Конструкты нуклеиновых кислот и вакцины из больших и малых т-антигенов полиомавируса клеток меркеля и способы их применения
EA201990010A1 (ru) Вакцина против вируса инфекционного бронхита
EA201691981A1 (ru) Улучшенные транспортные молекулы модулярного антигена и их применение
EA201990711A1 (ru) Новый ehv сайт инсерции orf70
EA202192923A1 (ru) Антитела и способы лечения инфекции, вызываемой вирусом гриппа а
EA201990719A1 (ru) Новые промоторы
MX2023003934A (es) Antigenos de consenso de filovirus, construcciones de acido nucleico y vacunas realizadas a partir de estos, y metodos para utilizarlos.
MX2021015766A (es) Nuevos antigenos y metodos contra el cancer.
EA202090628A1 (ru) Система экспрессии paramyxoviridae
WO2020065349A3 (en) Vaccines and methods
EA202190758A1 (ru) Композиция для индукции гибели клеток, имеющих мутированный ген, и способ индукции гибели клеток, имеющих мутированный ген, с применением композиции
BR112016030008A2 (pt) método para a detecção de infecção por pegivirus humano 2 em um indivíduo, para a detecção de ácido nucleico de pegivirus humano 2 e para a detecção de pegivirus humano 2 em uma amostra, e, composição